Pioglitazone (7·5 mg/day) added to flutamide–metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Summary: Background and aim Low‐dose pioglitazone (Pio), flutamide (Flu), metformin (Met) plus an oestro‐progestagen is a novel polytherapy lowering total and visceral adiposity, and reducing carotid intima media thickness (IMT) in hyperinsulinaemic women with androgen excess, without changing their body mass index (BMI). In a search for mediators of PioFluMet's actions, we measured serum levels of visfatin and high molecular weight (HMW) adiponectin. Design and patients In a double‐blind study, we enrolled 38 young women with hyperinsulinaemic androgen excess [mean BMI: 23·7 kg/m 2], all of whom started on Flu (62·5 mg/day), Met (850 mg/day) and a transdermal oestro‐progestagen, each for 21/28 days over 1 year. Patients were randomly assigned to receive, in addition, placebo (n = 19) or Pio (7·5 mg/day; n = 19) on the same 21/28 days. Measurements Serum concentrations of visfatin and HMW adiponectin, visceral fat by magnetic resonance imaging, carotid IMT by ultrasound, all carried out during study start and after 1 year. Results PioFluMet raised visfatin by a mean 84% and HMW adiponectin by 157% (P < 0·001), and reduced visceral fat and IMT by a mean 22% and 31% (both P < 0·001). Low‐dose Pio accounted for about half of the PioFluMet effects on IMT, visfatin and HMW adiponectin. Conclusion In hyperinsulinaemic women with androgen excess, low‐dose polytherapy with PioFluMet evoked striking rises in both circulating visfatin and HMW adiponectin, while lowering IMT and reducing visceral adiposity within 1 year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Visfatin: A Protein Secreted by Visceral Fat That Mimics the Effects of Insulin
Fukuhara, A., Matsuda, M., Nishizawa, M., Segawa, K., Tanaka, M., Kishimoto, K., Matsuki, Y., Murakami, M., Ichisaka, T., Murakami, H., et al. (2005) · Science · doi:10.1126/science.1097243 · Cited by 1,906
RetractedMatthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Gambineri, A., Patton, L., Vaccina, A., Cacciari, M., Morselli-Labate, A. M., Cavazza, C., Pagotto, U., & Pasquali, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2250 · Cited by 221
Increase in visfatin after weight loss induced by gastroplastic surgery
Krzyzanowska, K., Mittermayer, F., Krugluger, W., Kopp, H. P., & Schernthaner, G. (2006) · Obesity · doi:10.1038/oby.2006.219 · Cited by 71
Cited by
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
van Zuuren, E. J., Fedorowicz, Z., Carter, B., & Pandis, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010334.pub2 · Cited by 65
Luque-Ramírez, M., Nattero-Chávez, L., Ortiz Flores, A. E., & Escobar-Morreale, H. F. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx039 · Cited by 62
Hyperinsulinaemic androgen excess in adolescent girls
Ibáñez, L., Ong, K. K., López-Bermejo, A., Dunger, D. B., & de Zegher, F. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.58 · Cited by 56
Self-citationPCOS in Adolescence and Type 2 Diabetes
Carreau, A.-M., & Baillargeon, J.-P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-014-0564-3 · Cited by 40
Metadata
- Authors
- Ibáñez, L., López‐Bermejo, A., Díaz, M., Enríquez, G., Valls, C., & De Zegher, F.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2007-11-19
- Volume
- 68
- Issue
- 2
- Pages
- 317-320
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W1582550852
- Cited by
- 28
- References
- 4
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pioglitazone (7·5 mg/day) added to flutamide–metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. https://app.cochat.ai/papers/10.1111/j.1365-2265.2007.03137.x
- The paper
- Ibáñez, L., López‐Bermejo, A., Díaz, M., Enríquez, G., Valls, C., & De Zegher, F. (2008). Pioglitazone (7·5 mg/day) added to flutamide–metformin in women with androgen excess: additional increments of visfatin and high molecular weight adiponectin. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2007.03137.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.